PSC
Patient Square Capital Portfolio holdings
AUM
$277M
This Quarter Return
-9.77%
1 Year Return
+6.76%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$242M
AUM Growth
+$242M
(-9.6%)
Cap. Flow
+$3.52M
Cap. Flow
% of AUM
1.46%
Top 10 Holdings %
Top 10 Hldgs %
89.15%
Holding
24
New
4
Increased
12
Reduced
1
Closed
5
Top Buys
| 1 |
Scholar Rock
SRRK
|
$3.92M |
| 2 |
Kymera Therapeutics
KYMR
|
$3.89M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$3.41M |
| 4 |
Ocular Therapeutix
OCUL
|
$3.29M |
| 5 |
Mirum Pharmaceuticals
MIRM
|
$2.32M |
Top Sells
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.01M |
| 2 |
Liquidia Corp
LQDA
|
$4.98M |
| 3 |
Geron
GERN
|
$4.68M |
| 4 |
SWTX
SpringWorks Therapeutics
SWTX
|
$3.37M |
| 5 |
Arvinas
ARVN
|
$1.66M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Roivant Sciences
ROIV
$8.46B
| $126M | 52.09% |
12,480,000
| – | – |
|
2
Insmed
INSM
$30.7B
| $25.2M | 10.42% |
330,250
+23,083
| +8% | +$1.76M |
|
|
3
Liquidia Corp
LQDA
$2.46B
| $22.5M | 9.29% |
1,522,452
-337,919
| -18% | -$4.98M |
|
4
EyePoint Pharmaceuticals
EYPT
$809M
| $8.03M | 3.32% |
1,481,977
+71,646
| +5% | +$388K |
|
|
5
Ocular Therapeutix
OCUL
$2.21B
| $6.75M | 2.79% |
920,199
+449,280
| +95% | +$3.29M |
|
6
Cullinan Oncology
CGEM
$442M
| $6.65M | 2.75% |
878,897
| – | – |
|
7
Nurix Therapeutics
NRIX
$696M
| $5.31M | 2.2% |
447,296
+1,000
| +0.2% | +$11.9K |
|
|
8
Mirum Pharmaceuticals
MIRM
$3.73B
| $5.24M | 2.17% |
116,362
+51,462
| +79% | +$2.32M |
|
9
Enliven Therapeutics
ELVN
$1.24B
| $5M | 2.07% |
253,838
+29,800
| +13% | +$586K |
|
|
10
Scholar Rock
SRRK
$3.18B
| $4.95M | 2.05% |
154,000
+122,000
| +381% | +$3.92M |
|
11
Disc Medicine
IRON
$2.13B
| $4.12M | 1.7% |
83,000
+26,600
| +47% | +$1.32M |
|
12
Agios Pharmaceuticals
AGIO
$2.28B
| $4.09M | 1.69% |
139,732
+18,000
| +15% | +$527K |
|
|
13
Kymera Therapeutics
KYMR
$2.91B
| $3.89M | 1.61% |
+142,201
| New | +$3.89M |
|
14
Pharvaris
PHVS
$1.45B
| $3.85M | 1.59% |
245,496
+37,893
| +18% | +$595K |
|
15
Allogene Therapeutics
ALLO
$249M
| $3.46M | 1.43% |
2,368,186
+878,277
| +59% | +$1.28M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $3.41M | 1.41% |
+38,500
| New | +$3.41M |
|
17
Intellia Therapeutics
NTLA
$1.22B
| $1.66M | 0.68% |
232,781
+16,800
| +8% | +$119K |
|
18
Soleno Therapeutics
SLNO
$3.57B
| $1.33M | 0.55% |
+18,600
| New | +$1.33M |
|
19
VYNE Therapeutics
VYNE
$8.21M
| $406K | 0.17% |
+257,033
| New | +$406K |
|
|
20
Arvinas
ARVN
$580M
| – | – |
-86,627
| Closed | -$1.66M |
|
21
Astria Therapeutics
ATXS
$372M
| – | – |
-105,057
| Closed | -$939K |
|
|
22
Geron
GERN
$938M
| – | – |
-1,321,268
| Closed | -$4.68M |
|
|
SWTX
23
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-93,137
| Closed | -$3.37M |
|
|
ITCI
24
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| – | – |
-71,990
| Closed | -$6.01M |
|